Results 161 to 170 of about 99,805 (324)

Polypharmacy is a challenge for our generation, and the knowledge of deprescribing is a needed skill of our health care professionals

, 2022
Shadi Sarahroodi
openalex   +2 more sources

Change in body mass index and disease burden among people with obesity and multiple long‐term conditions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a risk factor for multiple long‐term conditions (MLTCs/multimorbidity). However, the impact of weight loss in people with MLTCs is unclear. We investigated the association between body mass index (BMI) change and the development of obesity‐related complications (ORCs), as well as clinical and economic outcomes in individuals ...
Kamlesh Khunti, Alex Mourer, Silvia Capucci, Lua Wilkinson, Klaus K. Andersen, Abd A. Tahrani, Camilla S. Morgen   +6 more
wiley   +1 more source

Relationship Between Polypharmacy and Medication Adherence in the Hypertensive Elderly Patients [PDF]

, 2020
Habib Shareinia, Leila Sadeghmoghadam, M. R. Mokhtarzadeh, Seyede Maryam Zahrayi, Nemat Jafari, Reza Noori   +5 more
openalex   +1 more source

Trends in polypharmacy and excessive polypharmacy: a retrospective national database analysis (2012-2021) [PDF]

, 2023
Lorenz Van der Linden, Jos Tournoy
openalex   +1 more source

Terbinafine‐Resistant Trichophyton Dermatophytosis in Australia

Australasian Journal of Dermatology, EarlyView.
Thuvarahan Jegathees, Zachary P. Holmes, Catherine Martin, Cindy Kalai, Catherine Voutier, Denis Spelman, Gemma Robertson, Johannes S. Kern   +7 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Long‐term outcomes of stereotactic radiofrequency ablation in hypothalamic hamartomas: A single‐center experience

Epilepsia, EarlyView.
Abstract Objective Hypothalamic hamartomas (HHs) lead to refractory epilepsy, and minimally invasive surgical approaches are standard of care for affected patients. Stereotactic radiofrequency thermocoagulation (SRT) is one of the treatment methods recognized to achieve seizure freedom. This study reports surgical outcome from a single center reporting
Peter Christoph Reinacher, Julia Jacobs, Mukesch Johannes Shah, Theo Demerath, Kathrin Wagner, Victoria San Antonio‐Arce, Horst Urbach, Volker Arnd Coenen, Andreas Schulze‐Bonhage, Kerstin Alexandra Klotz   +9 more
wiley   +1 more source

Non-pharmacological Approaches to Treatment of Patients over 60 Years as a Way to Improve Pharmacotherapy Safety and Prevent Polypharmacy

, 2018
А. П. Переверзев, О. Н. Ткачева, Yu. V. Kotovskaya, Yu. S. Onuchina, Е. N. Dudinskaya, A. V. Naumov   +5 more
openalex   +2 more sources

Teaching Deprescribing and Combating Polypharmacy in the Pharmacy Curriculum: Educational Recommendations from Thematic Analysis of Focus Groups [PDF]

, 2023
Devin Scott, Alina Cernasev, Rachel E. Barenie, Sydney Springer, David R. Axon   +4 more
openalex   +1 more source

Characteristics, therapeutic pathway and the economic burden of patients with drug‐resistant epilepsy: A real‐world analysis following the introduction of cenobamate in Italy

Epilepsia, EarlyView.
Abstract Objectives Drug‐resistant epilepsy (DRE) remains a major clinical challenge, affecting approximately one‐third of patients with epilepsy. Cenobamate, a novel antiseizure medication (ASM) approved in Italy in 2022, has shown promise in clinical trials. However, real‐world data on its use, especially economic evaluations, remain limited.
Valentina Perrone, Chiara Veronesi, Maria Cappuccilli, Margherita Andretta, Marcello Bacca, Antonietta Barbieri, Fausto Bartolini, Alessandro Brega, Maria Rosaria Cillo, Francesco Colasuonno, Stefania Dell'Orco, Fulvio Ferrante, Stefano Grego, Antonella Lavalle, Daniela Mancini, Maurizio Pastorello, Romina Pagliaro, Cataldo Procacci, Camilla Scandolara, Patrizia Schiavone, Loredana Ubertazzo, Paola Valpondi, Adriano Vercellone, Alberto Zucchi, Maria Ciappetta, Domenico Lucatelli, Andrea Cinti Luciani, Luca Degli Esposti   +27 more
wiley   +1 more source